Introduction
The development of effective vaccines against intracellular infectious agents is one of the biggest challenges in science and an urgent unmet medical need. In addition, other highly prevalent diseases like cancer strongly require new vaccination strategies that promote effective and long lasting cytotoxic CD8 + T-cell (CTL) responses.
With the discovery of dendritic cells (DCs) in 1973 by the Nobel Prize laureate Ralph
Steinman, a new window of opportunities opened in vaccine development. Consequently, for many years efforts have been made to develop vaccines based on ex vivo generated DCs carrying specific antigens from tumours or pathogens [1] . Although these studies showed promising results in mice and in a number of clinical studies, the production of antigenbearing cellular DC vaccines is a labour intensive and costly procedure [1] . Therefore, it hardly represents an option to vaccinate against infectious diseases like tuberculosis, malaria or HIV, which mainly affect developing countries. More recently, a new strategy has been explored to target defined antigens to DCs by using antibodies or glycosylated molecules that bind specific surface receptors directly in vivo [2] [3] [4] . Many of the receptors studied for DC targeting purposes belong to the family of C-Type lectin receptors (CLRs) such as DEC-205 (CD205) [2, 5, 6] , macrophage mannose receptor (MMR) [7] and Clec9A [6, 8] , which represent antigen uptake receptors that internalise antigen for loading MHC molecules.
Amongst the above mentioned surface receptors, the best-studied example for antigen delivery to DCs is DEC-205. DEC-205 is an endocytic CLR found on the surface of a subgroup of conventional DCs (cDCs) present in the T-cell areas of LNs [9] with a high capacity to cross-present antigens to CD8 + T cells [5, 10] . Antibodies against DEC-205 conjugated to OVA have been shown to induce potent CD8 + and CD4 + T-cell responses, when used in combination with adjuvants [5, 11] . Moreover, this vaccination strategy has successfully provided protective antigen-specific immune responses against tumours [2] and HIV antigens [6, 12, 13] . Some of these conjugated antibodies, such as anti-MMR [7] and anti-DEC-205 (CDX-1401; Celldex Therapeutics) have even entered clinical trials. Yet, in humans, the expression pattern of DEC-205 and the MMR is less DC-restricted than in mice [1, 7, 14] . Therefore, targeting these receptors in humans carries a risk of undesired side effects and high antibody doses might be required to achieve adequate immune responses.
DC-SIGN is a C-type lectin receptor initially described as a surface molecule present on cDCs that mediates innate recognition of various pathogens [15] [16] [17] . One advantage of DC-SIGN over other receptors for delivering antigens in vivo is the specificity of its expression.
DC-SIGN is mainly found on human immature DCs and at low levels on mature DCs and macrophages [15, 16] , as well as on a small subset of blood plasmacytoid DCs (pDCs) [16, 18] . Targeting DC-SIGN via anti-DC-SIGN antibodies [19] or Lewis oligosaccharides [3, 4, 20] conjugated to a model antigen, has been shown to induce potent T-cell proliferative responses both in vivo and in vitro, and also inhibited tumour growth in a humanised mouse model [4, 21] . However, little is known on the efficacy of DC-SIGN targeting vaccines to induce protective responses against pathogens.
Listeria monocytogenes, a Gram-positive bacterium, is one of the best-characterised models to study vaccines against intracellular pathogens, since clearance of this bacterium is strongly dependent on CD8 + T-cell responses [22] . Therefore, we used L. monocytogenes expressing OVA (LM-OVA) as a model organism to test the efficacy of an OVA conjugated anti-human-DC-SIGN (αDC-SIGN:OVA) antibody vaccine. Using the previously described hSIGN mouse [23] we here show that targeting antigens to DCs via DC-SIGN induces a robust antigen-specific response in vivo that leads to rapid clearance of L. monocytogenes infection.
Thus, for the first time, this study provides in vivo evidence that anti-DC-SIGN conjugated antibodies can be used as a vaccination strategy against intracellular pathogens.
Results

In vitro targeting of antigen to DCs via DC-SIGN induces efficient T-cell proliferation
Delivery of antigens to DCs via specific antibodies against surface receptors can induce antigen-specific T-cell proliferation. In particular, DC-SIGN targeting has been shown to induce efficient cross-presentation by human DCs [19, 24] . To determine whether antigen presentation can also be induced by murine DCs expressing the human DC-SIGN receptor [23] Fig.1 A,B). The capacity of antibody-targeted WT and hSIGN BMDCs to present OVA was evaluated by co-culturing them with CD4 + OT-II or CD8 + OT-I T cells bearing an OVA specific MHC-class-II or -I restricted TCR respectively. As determined by 3 H-thymidine incorporation, proliferation of OT-II and OT-I T cells in response to BMDCs loaded with soluble OVA (30 µg/mL) was comparable in WT and hSIGN BMDC cultures, suggesting that expression of the human transgene does not affect the capacity of the DCs to process and present antigens to T cells (Fig.1A,B) . Instead, OT-II and OT-I T-cell proliferation induced by hSIGN BMDCs targeted with αDC-SIGN:OVA (0.5 µg/mL) was significantly higher than proliferation induced by WT BMDCs targeted in the same way (Fig.1A,B) . Targeting WT or hSIGN BMDCs with a similar amount of soluble OVA (0.5 µg/mL) or the same concentration of isotype:OVA induced only marginal proliferation in both OT-II and OT-I cultures (Fig.1A,B) . To determine whether proliferation in response to αDC-SIGN:OVA was dosedependent, we next evaluated the total number of proliferating OT-II and OT-I T cells using CFSE-based proliferation assays. As shown in (Fig.3A) , suggesting that this immunisation strategy is highly efficient in expanding CD8 + T cells with the capacity to produce IFN-γ.
We next asked whether these expanded cells also display cytotoxic activity. To address this issue, we used a modified protocol to analyse specific killing [25] . intravenously with 5x10 4 LM-OVA (Fig.4A) . To determine the effect of αDC-SIGN:OVA/αCD40 vaccination on the endogenous CD8 + T cell pool, mice were bled before infection, and OVA-specific CD8 + T cells were determined by SIINFEKL-pentamer staining.
At this time point, increased levels of antigen-specific CD62L low SIINFEKL-specific CD8 + T cells were detected in the blood of vaccinated hSIGN mice, but not in vaccinated WT or nonvaccinated mice (Fig.4B,C) . Consequently, the bacterial burden in the liver and spleen of vaccinated hSIGN mice, was significantly lower than in vaccinated WT or non-vaccinated mice 3 days after infection (Fig.4D,E) . The lower bacterial burden was accompanied by higher frequencies of CD8 + IFN-γ-producing T cells present in the spleen of infected hSIGN mice vaccinated with αDC-SIGN:OVA/ αCD40 compared with that in control mice (Fig.4F ).
Taken together, our results demonstrate that DC-SIGN vaccination, leads to the expansion of the (non-transgenic) endogenous pool of CD8 + OVA-pecific T cells that can efficiently control L. monocytogenes infection.
Vaccination with αDC-SIGN plus αCD40 induces long-lasting protective immunity
Another important aspect in the design of new vaccination strategies is their capacity to provide long-lasting immunity. Therefore, we next studied the efficacy of DC-SIGN targeting following a standardised long-term protocol [26] . Briefly, a single dose of αDC-SIGN:OVA plus αCD40 was given intraperitoneally to WT and hSIGN mice and 21 days later the animals were boosted with OVA/IFA subcutaneously (Fig.5A ). On day 35 after the initial vaccination, mice were bled to determine the levels of OVA-specific antibodies and subsequently infected with 2x10 5 CFU LM-OVA intravenously. While both WT and hSIGN mice showed augmented levels of OVA-specific IgG1 when compared to non-vaccinated mice (Fig.5B) , a significant increase in the level of OVA-specific Th1-associated IgG2c was only observed in vaccinated hSIGN mice, but not in vaccinated WT mice or in mice that were not vaccinated ( Fig.5C and Supporting Information Fig.7A ). After infection, bacterial burden in the spleen and liver of vaccinated hSIGN mice was significantly lower than in vaccinated WT or nonvaccinated mice (Fig.5D and Supporting Information Fig.7B ). This was accompanied by higher frequencies of CD62L low SIINFEKL-specific CD8 + T cells in the spleen and blood of hSIGN vaccinated mice but not in vaccinated WT or non-vaccinated mice (Fig.5E and data not shown). Although the OVA/IFA boost alone also caused a reduction in the CFU mainly in the liver, hSIGN mice that received the combination of of αDC-SIGN:OVA and OVA/IFA boost showed slightly lower bacterial load than the OVA/IFA boost alone. Interestingly, the reduction in CFU induced by the boost alone was not accompanied by an increase in the frequencies of CD62L low SIINFEKL-specific CD8 + T cells (Fig.5E ). More importantly, longlasting immunity was also achieved when only one administration of αDC-SIGN:OVA plus αCD40 was performed without an additional OVA/IFA boost (Fig.5D ).
Therefore, these results indicate that a single injection of αDC-SIGN:OVA plus αCD40
followed by a boost, can induce a long-lasting and antigen-specific cellular and humoral immunity which provides protection against L. monocytogenes infections.
Discussion
Vaccinations offer one of the most powerful tools in medicine to control infectious diseases.
However, attempts to use common vaccine strategies against many important intracellular infectious agents remain unsuccessful [27] . A prerequisite for effective vaccination against intracellular pathogens is the induction of a long-lasting CD8 + T-cell response that is able to induce sterilising immunity. Here, we made use of a recently described method to deliver antigens to DCs via conjugated or recombinant antibodies carrying a specific antigenic protein [1] . We focused on DC-SIGN, a C-type lectin receptor, which acts via capturing and internalising pathogens for antigen presentation to T cells [17, 28] . In this study we provide for the first time evidence that targeting a human DC receptor in vivo can induce a protective CTL immune response against the intracellular pathogen L.
monocytogenes. Thus, although further studies using anti-DC-SIGN antibodies conjugated to clinically relevant antigens might be necessary, we propose DC-SIGN as a novel candidate for DC-based vaccine strategies against intracellular pathogens. 
Materials and methods
Mice
Flow cytometry
The following antibodies and reagents were purchased from eBioscience: anti-CD11c (N418),
anti-CD8α (53-6.7), anti-CD4 (GK1. Dead cells were excluded by PI, DAPI, ethidium bromide monoazide (EMA), all from Sigma, or Aqua fluorescent reactive dye (Invitrogen) staining. Cellular aggregates were excluded by gating singlets as described in the Supporting Information. SIINFEKL-specific CD8 + T cells were stained using H2k b -SIINFEKL-specific pentamer (ProImmune) for 1h in the dark on ice.
In vitro proliferation assay
GM-CSF derived BMDCs were generated from BM cells using standard protocols [44] . On 
Vaccination with anti-DC-SIGN:OVA antibodies
The monoclonal anti-DC-SIGN antibody (clone: AZN-D1, IgG1) used in this study was previously described [15] . Briefly, the AZN-D1 or an isotype control antibody (10E2, antihuman Langerin, mouse IgG1,κ) were conjugated to OVA using the cross-linking agent into the tail base and the neck, 21 days after primary immunisation [26] .
In vivo T-cell priming
One day before immunisation, 2-3x10 6 OVA-specific congenic CD45. Brefeldin A (eBioscience) was added for additional 3h before staining.
In vivo cytotoxicity assay
WT or hSIGN mice were adoptively transferred with 3. 
Listeria monocytogenes infection
Vaccinated and non-vaccinated control mice were infected intravenously with a low dose LM-OVA (5x10 4 CFU, short-term vaccination protocol) to analyse the primary immune response, or a high dose (2x10 5 CFU , long-term vaccination protocol) to investigate a secondary immune response. The OVA-expressing L. monocytogenes 140403s strain (DMX, Philadelphia) was kindly provided by H. Shen [45] . LM-OVA was grown in Tryptic Soy Broth (TSB, BD, Biosciences) until early log phase. Bacterial density was adjusted according to a standard growth curve after measuring OD at 600 nm . Bacterial burden was determined in liver and spleen of infected mice. Livers were collected in 1mL sterile PBS (Gibco) and mechanically disrupted. Spleens were lysed using 0.1% v/v Triton-X in dH 2 O. Suspensions were plated in serial dilutions on TSB agar containing 50µg/mL erythromycin (Sigma). CFUs were calculated after incubating agar plates for 2 days at 37°C.
ELISA
OVA-specific IgG1 and IgG2c were assessed in serum samples by ELISA as previously described [46] . To evaluate antibody concentrations IgG1 (clone OVA-14, Sigma) was used as a standard. IgG2c was assessed by measuring serum dilutions from 1:500 to 1:8000.
Biotinylated anti-mouse IgG1 (A85-1, Pharmingen) or alkaline phosphatase conjugated antimouse IgG2c (Southern Biotech) antibodies were used.
Statistical analysis
Data analysis was performed using GraphPad Prism Software 5.0. Statistics were calculated *p<0.05; **p<0.01; Mann-Whitney t-test.
